Development of novel prognostic evaluation and therapy of hematological neoplasms in dogs and cats

本文建立了犬淋巴肿瘤微小残留病基因分析方法，并对临床疗效和预后评估有重要意义。此外，阐明了多种肿瘤相关因子异常，一部分参与了结局，并表明与候选新治疗靶分子有关。此外，建立了猫淋巴瘤的细胞形态学分类，并阐明了根据分类的恶性程度与结局显著相关。另一方面，分子靶向药物在犬肥大细胞瘤中的抗肿瘤效果分析，结果显示了新的治疗策略的潜力。此外，基因突变和犬肥大细胞瘤的恶性分类参与治疗效果和结果。这些结果对于指导治疗和评估动物血液肿瘤的预后是非常有用的。

The minimal residual disease assay by the gene analysis in canine lymphoid neoplasms was established and showed extremely useful for curative effect and a prognostic evaluation. In addition, plural tumor-related factors abnormality was clarified, and a part participated in the outcome and indicated to be with candidate novel treatment target molecules. Furthermore, the cytomorphological classification in feline lymphomas was established and it was clarified that the malignancy according to the classification was significantly associated with the outcome. On the other hand, antitumor effects of molecular target agents were analyzed in canine mastocytoma and the results showed potentials of novel treatment strategy. Furthermore, genetic mutations and the malignancy classification of canine mastocytoma participated in treatment efficacy and the outcome. The results are extremely useful for treatment guidelines and the prognostic evaluation in hematological neoplasms of animals.